Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. May 28, 2013; 19(20): 3052-3061
Published online May 28, 2013. doi: 10.3748/wjg.v19.i20.3052
Published online May 28, 2013. doi: 10.3748/wjg.v19.i20.3052
Figure 1 Neoadjuvant-intensified treatment protocol.
Patients received 50.4 Gy (solid arrows) or 54.0 Gy (dashed arrows) of radiation therapy (RT), 28 d (solid arrows) or 30 d [dashed arrows of fluorouracil (5-FU) and five (solid arrows) or six (dashed arrow)] weekly cycles of oxaliplatin dependent on performance status, clinical lymph node involvement, and potential risk of a non-sphincter-conserving surgical procedure. Radiation therapy was delivered with a 3-D-conformational multiple field technique at a daily dose of 1.8 Gy/fraction. All patients received a central venous access (port-a-cath) for delivering chemotherapy. Chemotherapy consisted of a 2-h oxaliplatin infusion (50 mg/m2) on the first day of each week of radiotherapy, and five daily continuous infusions of 5-FU (200 mg/m2).
- Citation: Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, Raffetto N, Tombolini V. Neoadjuvant-intensified treatment for rectal cancer: Time to change? World J Gastroenterol 2013; 19(20): 3052-3061
- URL: https://www.wjgnet.com/1007-9327/full/v19/i20/3052.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i20.3052